Shots:

• The CHMP has granted positive opinion to Cejemly (sugemalimab) + CT as a 1L treatment of metastatic NSCLC
• The positive opinion was supported by the P-III (GEMSTONE-302) study, demonstrating improvement in PFS & OS with sugemalimab + CT vs PBO + CT among treatment-naïve stage IV NSCLC patients. Results were published in The Lancet Oncology & Nature Cancer as well as highlighted international academic conferences
• The marketing application of the combination is under review with MHRA for the same indication and is under discussions with the EMA, MHRA & US FDA for other indications. Additionally, it is seeking collaborations for sugemalimab apart from a deal Ewopharma in Central Eastern Europe and Switzerland

Ref: CStone | Image: CStone 

Related News:- CStone Reports P-III Study (GEMSTONE-304) Results of Sugelimab as 1L Treatment of Esophageal Squamous Cell Carcinoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com